Keyphrases
Hepatocellular Carcinoma
100%
Liver
32%
Liver Transplantation
24%
Hepatic Stellate Cells
22%
Fibrosis
21%
Cirrhosis
18%
Tumor
17%
Liver Fibrosis
16%
Hepatic Fibrosis
15%
Hepatitis C Virus
14%
Hepatic Stellate Cell Activation
13%
Resection
12%
Nonalcoholic Steatohepatitis
12%
Advanced Hepatocellular Carcinoma
11%
Sorafenib
10%
Overall Survival
10%
Antifibrotic
10%
Hepatitis C
10%
Stellate Cells
9%
Chronic Liver Disease
8%
Kruppel-like Factor 6 (KLF6)
8%
Fibrogenic
8%
Transplantation
8%
Intrahepatic Cholangiocarcinoma (iCCA)
7%
Liver Cancer
7%
Liver Disease
7%
Alpha-fetoprotein
7%
Fibrogenesis
7%
Magnetic Resonance Imaging
7%
Liver Injury
6%
Non-alcoholic Fatty Liver Disease (NAFLD)
6%
Transforming Growth Factor-β
6%
Liver Resection
6%
Hepatocellular Carcinoma Surveillance
6%
Clinical Trials
6%
Hepatocytes
5%
Confidence Interval
5%
Diffusion-weighted Imaging
5%
Immune Checkpoint Inhibitors
5%
Liver Transplant Recipients
5%
Risk Factors
5%
Hazard Ratio
5%
Microvascular Invasion
5%
Apparent Diffusion Coefficient
5%
Cholangiocarcinoma
5%
Chronic Hepatitis C
5%
Orthotopic Liver Transplantation
5%
Dynamic Contrast-enhanced Magnetic Resonance Imaging (DCE-MRI)
5%
Hepatitis C Virus Infection
5%
Medicine and Dentistry
Hepatocellular Carcinoma
92%
Neoplasm
30%
Liver Transplantation
27%
Magnetic Resonance Imaging
24%
Liver Fibrosis
22%
Fibrosis
22%
Hepatic Stellate Cell
19%
Liver Cirrhosis
18%
Surgery
16%
Disease
15%
Malignant Neoplasm
13%
Nonalcoholic Fatty Liver
13%
Hepatitis C
12%
Fibrogenesis
12%
Cholangiocarcinoma
11%
Liver Graft
11%
Recurrent Disease
10%
Hepatectomy
10%
Liver Cancer
9%
Hepatitis C Virus
9%
Liver Disease
9%
Stellate Cell
9%
Liver Injury
9%
Overall Survival
9%
Diffusion MRI
8%
Biological Marker
7%
Cell Activation
7%
Transplantation
6%
Chronic Liver Disease
6%
Living Donors
6%
Hepatocyte
5%
Sorafenib
5%
Immunity
5%
Gadoxetic Acid
5%
Immunotherapy
5%
Transcatheter Arterial Chemoembolization
5%
Immune Checkpoint Inhibitor
5%